The autosomal dominant form of polycystic kidney disease is a very frequent genetically heterogeneous inherited condition affecting approximately 1 : 1000 individuals of the Caucasian population. The main symptom is the formation of fluid-filled cysts in the kidneys, which grow progressively in size and number with age, and leading to end-stage renal failure in approximately 50% of patients by age 60. About 85% of cases are caused by mutations in the PKD1 gene on chromosome 16p13.3, which encodes for polycystin-1, a membranous glycoprotein with 4302 amino acids and multiple domains. Mutation detection is still a challenge owing to various sequence characteristics that prevent easy PCR amplification and sequencing. Here we attempted a systematic screening of part of the duplicated region of the gene in a large cohort of 53 Hellenic families with the use of single-strand conformation polymorphism analysis of exons 16 ± 34. Our analysis revealed eight most probably disease causing mutations, five deletions and three single amino acid substitutions, in the REJ domain of the protein. In one family, a 3-bp and an 8-bp deletion in exons 20 and 21 respectively, were co-inherited on the same PKD1 chromosome, causing disease in the mother and three sons. Interestingly we did not find any termination codon defects, so common in the unique part of the PKD1 gene. In the same cohort we identified 11 polymorphic sequence variants, four of which resulted in amino acid variations. This supports the notion that the PKD1 gene may be prone to mutagenesis, justifying the relatively high prevalence of polycystic kidney disease.
Introduction
It is estimated that about 85% of autosomal dominant polycystic kidney disease (ADPKD) cases are caused by mutations in the PKD1 gene on chromosome 16p13.3 and the rest are caused by mutations in another gene, PKD2 on chromosome 4q22.
1,2 A third gene, PKD3, has been suggested by some to be implicated in rare families 3 and disputed by others. 4 Polycystic kidney disease is considered one of the most common diseases in the Caucasian population, with a prevalance of about 1 : 1000, and is the most common cause of inherited end-stage renal failure. The cardinal feature is the formation of fluid-filled cysts in the kidneys but other symptoms include hypertension, macroscopic or microscopic hematuria and liver cyst formation, among others. 5, 6 The C-terminal cytoplasmic domains and they produce a regulated Ca 2+ permeable cation channel. 9 ± 12 The molecular pathogenesis may involve the need for a somatic second hit that inactivates the inherited normal PKD allele, thereby leading to cystogenesis. 13 ± 16 More recent work provided genetic evidence in favour of polycystin-1 and -2 interaction by showing that in certain cases a somatic second hit in the PKD2 gene may be sufficient to cause disease in ADPKD1 patients, leading to a trans-heterozygous situation. 2, 17 Interestingly, germinal trans-heterozygosity caused by co-inheritance of PKD1 and PKD2 mutations was also reported. 18 Mutations of all kinds, including small insertions and deletions, missence mutations and termination codons have been characterised in more than 150 families by various laboratories. In most cases each family has its own unique mutation, but in rare occasions the same mutation has been found in more than one non-related family and even in families with different ethnic origin. 19 ± 25 Factors that have been considered to contribute to the PKD1 gene mutagenesis are the high GC content, the large size, 14-kb, of the mRNA 26, 27 and the presence of the longest known polypyrimidine tract of 2.5-kb around intron 21.
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Also, some mutations have been occasionally attributed to gene conversion events, as a result of the presence of at least three other highly homologous genes elsewhere on chromosome 16.
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In this study we are presenting the first systematic search for mutations in a large part of the duplicated region of the PKD1 gene in a large cohort of ADPKD Hellenic families from Greece. Surprisingly, most mutations found are novel deletions of triplets, representing single aminoacids, or larger deletions that lead to frameshift defects. On one PKD1 chromosome we identified two deletions on different exons, a 3-bp deletion and an 8-bp deletion, both of which we believe are pathogenic. Also, we identified a plethora of missence and neutral polymorphic variants, once again supporting the notion that this gene has high tolerability of DNA sequence variation.
Materials and methods
Clinical information DNA samples from 53 Hellenic ADPKD families from Greece (24) and Cyprus (29) were included in this study. For some of them we had linkage analysis data suggesting linkage to the PKD1 gene. For the rest no adequate data were available for linkage analysis, or they were single patient families. However, since 85 ± 90% of all ADPKD cases are due to mutations in the PKD1 gene, they were included in a systematic screening for mutations in the duplicated region of the PKD1 gene.
DNA extraction and LR-PCR
DNA extraction was performed using the salting out procedure. 30 The LR-PCR encompassing exons 23 ± 34 was performed according to the conditions described. 15 Plasmid preparations were made by using a kit from Qiagen (Qiagen GmbH, Hilden, Germany). Sequencing was performed using purified recombinant plasmid DNA. Alternatively, DNA was rapidly extracted by boiling from single colonies, and the insert was specifically amplified by PCR and sequenced directly.
Results and discussion
Samples from 53 unrelated Hellenic families were screened for mutations in the duplicated part of the PKD1 gene by SSCP analysis. Sequencing of samples showing altered SSCP pattern revealed a number of interesting sequence variants, including clearly pathogenic or putatively pathogenic mutations, in addition to multiple polymorphisms. Eight novel mutations were found in a region of the PKD1
Novel deletions in Hellenic ADPKD families I Bouba et al 678 gene that represents 23% of the coding region, exons 16 ± 21 (Table 2) , as well as several polymorphisms, some of which result in aminoacid substitutions (Table 3) . Interestingly no nonsense mutation was identified in the duplicated region of the PKD1 gene investigated in this series of experiments.
Mutations
Deletions 7174-7192del14 (14-bp deleted anywhere therein) SSCP analysis with primers I15F1 ± I16R1 in exon 16 revealed an abnormal pattern. Subsequent cloning and sequencing revealed a 14-bp deletion which causes a translation frame- shift leading to putative incorporation of 93 novel aminoacids before reaching a translation STOP codon. It is difficult to define the exact nucleotide position where the deletion appeared, owing to the fact that this deletion is surrounded by a 5-bp direct repeat sequence, CACGG ( Figure 2 ). It is interesting that this nucleotide stretch occurs 32 times within the entire PKD1 coding cDNA, when based on statistics it is expected to occur only 12 times. This may partly be explained by the general GC richness of the gene (67.2% GC). This deletion was present in two apparently unrelated families originating from the Ioannina prefecture in the north-west of Greece. No haplotype analysis could be performed.
7946del3 (G2579del), 8047del3(L2613del), 9142del3 or 9143del3 (F2978del) An altered SSCP pattern was obtained in exon 20. Sequencing revealed a 3-bp deletion which corresponds to amino acid Gly at codon 2579 (G2579del). Heteroduplex analysis on LR-PCR products obtained from the available mother and the three children, revealed that all had inherited the same deletion, co-segregating with the disease. Also, these same patients had inherited another variation, 8183del8 (see below). The G2579del occurred within a 10-bp imperfect direct repeat (Figure 3 ). Another 3-bp deletion was identified in exon 20 of a separate single patient, which resulted in the deletion of Leu at codon 2613. And thirdly, a 3-bp deletion was detected in exon 24 of a mother and offspring, abolishing amino acid Phe at codon 2978. In these three cases of single aminoacid deletions, although tempting to implicate them in disease development, in the absence of functional studies and being unable to screen the entire sequence of the PKD1 gene, the data should be interpreted with caution. At the same time, in favour of them being pathogenic and not neutral polymorphisms, is their presence in single families among 53 tested here and among many others tested in other laboratories. It should be mentioned that F2978del occurred within a polypyrimidine-rich 23-bp sequence (87% CT). Within the same 23-bp stretch another 9-bp deletion was reported as a somatic mutation in a renal cyst of a PKD1 patient. 2 Such polypyrimidine-rich sequences may represent mutational hotspots due to potential formation of triple helical conformations. 33, 34 8183del8 (Frameshift after 2657) In the same family of four clinically affected members who carried the G2579del mutation, a 8-bp deletion in exon 21 was also identified. Cloning and sequencing experiments showed that the two d : These nucleotide changes occurred on the same chromosome and individual's homozygous for these polymorphisms were observed during this work.
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I Bouba et al 680 deletions were in cis position on the chromosome that was inherited from the affected mother (Figure 3 ). This 8-bp deletion is predicted to result in a translation frameshift after aminoacid 2657 and lead to a novel stop codon 483-bp downstream. Based in its nature 8183del8 is most likely a pathogenic defect. To our knowledge this is the first time that two putative pathogenic changes seen in cis position, are most probably not the result of gene conversion, as none was present on the homologous genes tested on hybrid cell line P-MWH2A. 20 An unusual pattern of mutation in the PKD1 was previously reported and gene conversion was considered a likely event. 21 Similar findings have been reported for the CFTR gene, mutations in which are responsible for Cystic Fibrosis and for the MEFV gene, mutations in which are responsible for Familial Mediterranean Fever. 35 Judging from Table 1 ). The deleted nucleotides are boxed and denoted by arrows (B). The 3-bp deletion G2579del occurred within a region that contained a direct 10-bp imperfect repeat (underlined, C). In the 10-bp repeat the residue at position 4, was either cytosine or guanosine and are shown with lowercase letters (C). Figure 2 Nucleotide sequence around the region of the mutation 7174 ± 7192del14 in exon 16. Antisense sequences were obtained after cloning of PCR products and multiple normal and mutant clones were analysed (A). The 14 residues deleted in the mutant PKD1 allele are boxed and denoted by arrows. The deletion occurred anywhere within the boxed 19-bp sequence (B). Notice that the boxed sequence is flanked by a direct 5-bp repeat (underlined). Interestingly the CACGG sequence is present 32 times within the coding region of PKD1 whereas statistically it is expected only 12 times.
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Possible missense mutations P2471L This mutation (7623C-4T) affects amino acid 2471 in exon 18 by replacing Pro, an iminoacid with cyclic structure which can cause bends on proteins, with Leu, an aliphatic non-polar amino acid. It creates a BbvI restriction site. The 260-bp PCR product of primer-pair E18F1/I19R1 is digested by BbvI into fragments 130, 65 and 34-bp in the presence of the T allele and into 164 and 65-bp in the presence of the C allele. The proline residue is conserved in murine and fugu genomes 36 (GenBank accession number AF013614), suggesting that this may indeed be the causative defect. This is the only substitution mutation presented in this work that occurred at a CpG dinucleotide, which is known to be prone to this kind of transition.
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Q2519L A transversion A-4T at position 7767 of exon 19 leads to a substitution of Leu for Gln. The non-charged but polar hydrophilic amino acid Gln is substituted by the nonpolar hydrophobic Leu. Gln is conserved in murine, but substituted by Asp in fugu genome. This amino acid substitution was present in both affected mother and son in this small family, CY1625, but was absent from another 52 ADPKD unrelated patients. However, the small size of the family does not exclude the possibility that this may represent a private polymorphism and not a causative mutation.
T2649I
Sequencing revealed a C-4T substitution at nucleotide position 8157 (ACT-4ATT), changing the amino acid Thr to Ileu at position 2649, in exon 21. It resulted to the replacement of a hydrophilic polar by a hydrophobic nonpolar amino acid. Thr is conserved in murine but is substituted by Ala in fugu.
There is as yet no functional test for the polycystin-1 protein. Therefore, missense mutations, and especially in small families, cannot always be regarded with certainty as the causative defects. However, these variants can be useful when presymptomatic or prenatal diagnosis is attempted by DNA linkage analysis. As regards the deletion mutations, which all occur in the extracellular REJ domain of polycystin-1, it is reasonable to hypothesise that they may interfere with the anchoring of the protein in the plasma membrane and the hypothesised signal transduction.
Polymorphisms
Eleven intragenic polymorphisms were found, representing neutral or coding variants (Table 3) In the same family (Gr-I-9) with the three and eight nucleotide deletions described above, a polymorphic haplotype of three polymorphisms in exon 20 was detected, 7919C, 7956T, 8002G. It was obvious that this haplotype was inherited from the healthy parent, and is also present as such in the homologous gene sequences we tested, raising the possibility of gene conversion as a mechanism for their generation ( Figure 3A ).
In conclusion, our findings of 19 mutations or variations in the 53 Hellenic families investigated here, confirm previous suggestions that the PKD1 gene is prone to mutations. 29, 34, 38 De novo mutations reported by several groups confirm this hypothesis. 24, 25, 39 The great rarity of some mutations and their confinement within certain families suggests also that they must have occurred very recently. In many cases multiple polymorphisms have been detected on same alleles, being in linkage disequilibrium. 40 This high variability has been attributed to the high GC content of the gene, the presence of the longest known polypyrimidine track (2.5-kb) and the presence of at least three highly homologous genes that have been shown to be responsible for gene conversion events. 29 Our data suggest that other features of the PKD1 gene such as random repeats and short CT-rich sequences scattered throughout the gene may contribute to mutagenesis (Figures 2 and 3) . The screening for mutations in this gene is still difficult, primarily because of the very long coding sequence, which prevents one from offering DNA analysis in a routine clinical setup. In this study we identified mutations only in 13% of our patients by screening a region that represents 23% of the PKD1 coding sequence. This discrepancy may be explained by the weakness of our approaches, as SSCP is not a 100% success method. Also, it may be partly explained by the fact that some of the patients belonged to very small families which could not be distinguished, either by clinical or molecular methods, from a PKD2 related disease. Interestingly, approximately 150 PKD1 mutations have been reported thus far 24, 39, 41 (Cardiff PKD1 mutation database http://archive.uwcm.ac.uk/uwcm/mg/search/120293.html) only four of which are located in exons 20, 21, whereas four out of eight reported here and four out of 13 identified in Hellenic families altogether, are also located in these exons ( Figure  1 ). Our findings partly support the early hypothesis that clustering of mutations was expected near the intron 21 polypyrimidine tract.
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We wish to emphasise that this is the first study describing a systematic screen for mutations in a large collection of polycystic kidney disease samples from Greece. Finally, we would like to believe that the characterisation of molecular defects and polymorphisms will allow the delineation of polycystin-1 functional domains and may lead to a genotype/ phenotype correlation. At the present time, only the last 112 C-terminal residues of polycystin-1 have been convincingly shown to be involved in the regulation of a calcium channel, most probably through interaction with polycystin-2. This explains why mutations as far C-terminal as C4086X and others, 19, 31, 42 which result in removing the crucial polycystin-1 fragment that is implicated in regulating a cation channel, 12 result also in cyst formation and disease development.
